Dexamethasone Oral Drops and Polatuzumab Vedotin-piiq
Determining the interaction of Dexamethasone Oral Drops and Polatuzumab Vedotin-piiq and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers. MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
- "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Generic Name: dexamethasone
Brand name: Baycadron, Decadron, Dexamethasone Intensol, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak, De-Sone LA, Dexacen-4, Dexasone, Dexasone LA, Solurex, Solurex LA
Synonyms: Dexamethasone, Dexamethasone (Systemic)
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dexamethasone Oral Drops-Polio vaccine, inactivated
- Dexamethasone Oral Drops-Poliovirus Vaccine (Inactivated)
- Dexamethasone Oral Drops-Poliovirus vaccine, inactivated Injection
- Dexamethasone Oral Drops-Polivy
- Dexamethasone Oral Drops-Polmon
- Dexamethasone Oral Drops-Polocaine
- Polatuzumab Vedotin-piiq-Dexamethasone SodiumPhosphate
- Polatuzumab Vedotin-piiq-Dexamethasone Solution (Drops)
- Polatuzumab Vedotin-piiq-Dexamethasone Tablets
- Polatuzumab Vedotin-piiq-Dexamethasone, neomycin, and polymyxin B ophthalmic
- Polatuzumab Vedotin-piiq-Dexasone injection
- Polatuzumab Vedotin-piiq-Dexasone LA injection